J1303 HCPCS code: Injection, ravulizumab-cwvz, 10 mg
J1303 is the HCPCS Level II code for injection, ravulizumab-cwvz, 10 mg. In 2024 Medicare paid an average of $171.57 per service for J1303 across 1,230,566 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 360 per day on outpatient hospital claims. Medicare volume rose 223% from 2022 to 2024 (380,589 to 1,230,566 services). In 2024, about 937 clinicians billed Medicare for J1303 for 808 beneficiaries; Texas, Florida, Illinois accounted for 33% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2019-10-01 |
| Last action effective | 2019-10-01 |
Who bills J1303 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 937 |
| Medicare beneficiaries | 808 |
| States with claims | 25 |
| Share of services in top 3 states (Texas, Florida, Illinois) | 33% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J1303, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 380,589 | 337 | $218.36 | $174.12 |
| 2023 | 891,341 | 616 | $216.17 | $172.22 |
| 2024 | 1,230,566 | 808 | $215.36 | $171.57 |
States with the most J1303 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Texas | 146,608 | $173.17 |
| Florida | 145,444 | $170.30 |
| Illinois | 71,211 | $173.45 |
| Tennessee | 62,512 | $171.01 |
| California | 60,469 | $172.96 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 360 | Prescribing Information |
| practitioner claims | 360 | Prescribing Information |
What changed for J1303
- 2019-10-01: J1303 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J1303?
J1303 is the HCPCS Level II code for injection, ravulizumab-cwvz, 10 mg. Short descriptor: "Inj., ravulizumab-cwvz 10 mg".
How much does Medicare pay for J1303?
In 2024, the average Medicare payment was $171.57 per service (average allowed $215.36).
Does Medicare cover J1303?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J1303 can be billed per day?
360 on outpatient hospital claims; 360 on practitioner claims (NCCI medically unlikely edits).
Related J13 codes
- J1300 — Injection, eculizumab, 10 mg
- J1301 — Injection, edaravone, 1 mg
- J1302 — Injection, sutimlimab-jome, 10 mg
- J1304 — Injection, tofersen, 1 mg
- J1305 — Injection, evinacumab-dgnb, 5mg
- J1306 — Injection, inclisiran, 1 mg
- J1307 — Injection, crovalimab-akkz, 10 mg
- J1308 — Injection, famotidine, 0.25 mg
- J1320 — Injection, amitriptyline hcl, up to 20 mg
- J1322 — Injection, elosulfase alfa, 1 mg
- J1323 — Injection, elranatamab-bcmm, 1 mg
- J1324 — Injection, enfuvirtide, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J1303
- Watch J1303 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J1303
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.